Cannabidiol in Cardiovascular Disease: A Review of Current Evidence and Future Directions.

Cannabidiol (CBD), a non-intoxicating compound found in cannabis, is emerging as a potential treatment for various heart conditions. Unlike THC, which produces a "high," CBD is attracting serious medical attention because it appears to reduce inflammation, protect cells from damage, and improve blood vessel function. Researchers have found that CBD may help with several cardiovascular issues including heart attacks, heart failure, inflammation of the heart lining (pericarditis), and dangerous heart rhythm problems. The compound seems to work through multiple mechanisms in the body, potentially reducing damage from heart attacks and preventing scarring of heart tissue.

However, translating this promise into actual medical treatments faces real challenges. While laboratory studies and early human trials show encouraging results, there are significant hurdles: researchers haven't established consistent dosing guidelines, clinical trials in humans remain limited, and regulatory authorities are still determining how to classify and regulate CBD as a medicine. The review identifies a clear gap between the exciting preclinical evidence and what doctors can confidently prescribe to patients today. More rigorous clinical trials are needed to determine the right doses, confirm CBD's safety in heart patients, and establish whether it truly works as well in humans as it does in laboratory settings.

For current and potential cannabis users, this research suggests CBD may have legitimate therapeutic potential for heart health, but it's premature to use it as a primary treatment for cardiovascular disease without medical supervision. Anyone considering CBD for heart conditions should consult their healthcare provider, as CBD may interact with other cardiovascular medications. The next few years of research will be critical in determining whether CBD becomes a recognized medical option or remains a promising but unproven compound.